238 related articles for article (PubMed ID: 34801749)
1. Efficacy of Aumolertinib (HS-10296) in Patients With Advanced EGFR T790M+ NSCLC: Updated Post-National Medical Products Administration Approval Results From the APOLLO Registrational Trial.
Lu S; Wang Q; Zhang G; Dong X; Yang CT; Song Y; Chang GC; Lu Y; Pan H; Chiu CH; Wang Z; Feng J; Zhou J; Xu X; Guo R; Chen J; Yang H; Chen Y; Yu Z; Shiah HS; Wang CC; Yang N; Fang J; Wang P; Wang K; Hu Y; He J; Wang Z; Shi J; Chen S; Wu Q; Sun C; Li C; Wei H; Cheng Y; Su WC; Hsia TC; Cui J; Sun Y; Ou SI; Zhu VW; Chih-Hsin Yang J
J Thorac Oncol; 2022 Mar; 17(3):411-422. PubMed ID: 34801749
[TBL] [Abstract][Full Text] [Related]
2. Aumolertinib: A Review in Non-Small Cell Lung Cancer.
Shirley M; Keam SJ
Drugs; 2022 Apr; 82(5):577-584. PubMed ID: 35305259
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of Limertinib (ASK120067) in Patients With Locally Advanced or Metastatic EGFR Thr790Met-Mutated NSCLC: A Multicenter, Single-Arm, Phase 2b Study.
Shi Y; Li B; Wu L; Pan Y; Pan Z; Liu Y; Fan Y; Ji Y; Fang J; Shi Q; Shi J; Gao H; Hu Y; Wang X; He Z; Ma R; Zhang Y; Jiang D; Bai Y; Zhang Y; Huang L; Zhou T; Liu H; Wang D; Wen Q; Chen G; Zang A; Wang X; Zhang X; Hu J; Yang R; Zhang G; Gu K; Wang L; Wang Q; Wei Z; Li Z; Lu H; Zhang H; Chen H; Song T
J Thorac Oncol; 2022 Oct; 17(10):1205-1215. PubMed ID: 35659581
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Rezivertinib (BPI-7711) in Patients With Locally Advanced or Metastatic/Recurrent EGFR T790M-Mutated NSCLC: A Phase 2b Study.
Shi Y; Wu S; Wang K; Cang S; Yao W; Fan Y; Wu L; Huang M; Li X; Pan Y; Yang Z; Zhu B; Chen G; Shi J; Sun M; Fang J; Wang L; Chen Z; Liu C; Li J; Liu J; Sun S; Zhao Y; Guo Y; Meng Z; Liu Z; Han Z; Lu H; Ma R; Hu S; Zhao G; Liu Z; Xie C; Zhong D; Zhao H; Yu H; Zhang L; Bi M; Yi S; Guo S; Yi T; Li W; Lin Y; Shu Y; Chen Z; Guo Z; Greco M; Wang T; Shen H
J Thorac Oncol; 2022 Nov; 17(11):1306-1317. PubMed ID: 36049654
[TBL] [Abstract][Full Text] [Related]
5. AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon-Small-Cell Lung Cancer With
Lu S; Dong X; Jian H; Chen J; Chen G; Sun Y; Ji Y; Wang Z; Shi J; Lu J; Chen S; Lv D; Zhang G; Liu C; Li J; Yu X; Lin Z; Yu Z; Wang Z; Cui J; Xu X; Fang J; Feng J; Xu Z; Ma R; Hu J; Yang N; Zhou X; Wu X; Hu C; Zhang Z; Lu Y; Hu Y; Jiang L; Wang Q; Guo R; Zhou J; Li B; Hu C; Tong W; Zhang H; Ma L; Chen Y; Jie Z; Yao Y; Zhang L; Jie W; Li W; Xiong J; Ye X; Duan J; Yang H; Sun M; Sun C; Wei H; Li C; Ali SM; Miller VA; Wu Q
J Clin Oncol; 2022 Sep; 40(27):3162-3171. PubMed ID: 35580297
[TBL] [Abstract][Full Text] [Related]
6. An evaluation of aumolertinib for the treatment of EGFR T790M mutation-positive non-small cell lung cancer.
Wang J; Wu L
Expert Opin Pharmacother; 2022 Apr; 23(6):647-652. PubMed ID: 35272542
[TBL] [Abstract][Full Text] [Related]
7. Safety, Efficacy, and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients With EGFR-Mutated Advanced NSCLC: A Multicenter, Open-label, Phase 1 Trial.
Yang JC; Camidge DR; Yang CT; Zhou J; Guo R; Chiu CH; Chang GC; Shiah HS; Chen Y; Wang CC; Berz D; Su WC; Yang N; Wang Z; Fang J; Chen J; Nikolinakos P; Lu Y; Pan H; Maniam A; Bazhenova L; Shirai K; Jahanzeb M; Willis M; Masood N; Chowhan N; Hsia TC; Jian H; Lu S
J Thorac Oncol; 2020 Dec; 15(12):1907-1918. PubMed ID: 32916310
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of Befotertinib (D-0316) in Patients With EGFR T790M-Mutated NSCLC That Had Progressed After Prior EGFR Tyrosine Kinase Inhibitor Therapy: A Phase 2, Multicenter, Single-Arm, Open-Label Study.
Lu S; Zhang Y; Zhang G; Zhou J; Cang S; Cheng Y; Wu G; Cao P; Lv D; Jian H; Chen C; Jin X; Tian P; Wang K; Jiang G; Chen G; Chen Q; Zhao H; Ding C; Guo R; Sun G; Wang B; Jiang L; Liu Z; Fang J; Yang J; Zhuang W; Liu Y; Zhang J; Pan Y; Chen J; Yu Q; Zhao M; Cui J; Li D; Yi T; Yu Z; Yang Y; Zhang Y; Zhi X; Huang Y; Wu R; Chen L; Zang A; Cao L; Li Q; Li X; Song Y; Wang D; Zhang S; Ding L; Zhang L; Yuan X; Yao L; Shen Z
J Thorac Oncol; 2022 Oct; 17(10):1192-1204. PubMed ID: 35724798
[TBL] [Abstract][Full Text] [Related]
9. Efficacy, safety, and genetic analysis of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small-cell lung cancer: a phase 2b, multicentre, single-arm, open-label study.
Shi Y; Hu X; Zhang S; Lv D; Wu L; Yu Q; Zhang Y; Liu L; Wang X; Cheng Y; Ma Z; Niu H; Wang D; Feng J; Huang C; Liu C; Zhao H; Li J; Zhang X; Jiang Y; Gu C
Lancet Respir Med; 2021 Aug; 9(8):829-839. PubMed ID: 33780662
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of SH-1028 in Patients With EGFR T790M-Positive NSCLC: A Multicenter, Single-Arm, Open-Label, Phase 2 Trial.
Xiong A; Ren S; Liu H; Miao L; Wang L; Chen J; Li W; Li R; Wang X; Lu Z; Wang D; Wu X; Liu Z; Xing L; Mao Y; Liu C; Zeng A; Niu H; Du Y; Sun Y; Pan Y; Hu Y; Zhang X; Chen X; Ma Z; Li N; Zhang J; Zhao M; Li X; Ye F; Li M; Yu G; Zhang X; Min J; Han D; Li J; Zhou C
J Thorac Oncol; 2022 Oct; 17(10):1216-1226. PubMed ID: 35798241
[TBL] [Abstract][Full Text] [Related]
11. A Phase 1/2 Study of Lazertinib 240 mg in Patients With Advanced EGFR T790M-Positive NSCLC After Previous EGFR Tyrosine Kinase Inhibitors.
Cho BC; Han JY; Kim SW; Lee KH; Cho EK; Lee YG; Kim DW; Kim JH; Lee GW; Lee JS; Shim BY; Kim JS; Chun SH; Lee SS; Kim HR; Hong MH; Ahn JS; Sun JM; Lee Y; Lee DH; Kang JA; Lee N; Kwon MJ; Espenschied C; Yablonovitch A; Ahn MJ
J Thorac Oncol; 2022 Apr; 17(4):558-567. PubMed ID: 34958928
[TBL] [Abstract][Full Text] [Related]
12. [Initial Treatment of Aumolertinib in Combination with Bevacizumab for Advanced NSCLC with Primary EGFR T790M Mutation: A Report of Three Cases and Literature Review].
Yang X; Meng F; Zhong D
Zhongguo Fei Ai Za Zhi; 2023 Feb; 26(2):158-164. PubMed ID: 36872054
[TBL] [Abstract][Full Text] [Related]
13. Central nervous system efficacy of rezivertinib (BPI-7711) in advanced NSCLC patients with EGFR T790M mutation: A pooled analysis of two clinical studies.
Yang S; Wu S; Zhao Y; Chen G; Zhu B; Li X; Wang K; Shi J; Cang S; Yao W; Fan Y; Fang J; Zhang L; Zhou J; Wu L; Zheng R; Huang M; Pan Y; Yang Z; Sun M; Yu H; Wang D; Huang J; Wang L; Shu Y; Chen Z; Liu C; Li J; Liu J; Sun S; Guo Y; Meng Z; Liu Z; Han Z; Wu G; Lu H; Ma R; Hu S; Zhao G; Zhang L; Liu Z; Xie C; Zhong D; Zhao H; Bi M; Yi S; Guo S; Yi T; Li W; Lin Y; Chen Z; Zhuang Z; Guo Z; Greco M; Wang T; Zhou A; Shi Y
Lung Cancer; 2023 Jun; 180():107194. PubMed ID: 37163774
[TBL] [Abstract][Full Text] [Related]
14. A phase I study of FCN-411, a pan-HER inhibitor, in EGFR-mutated advanced NSCLC after progression on EGFR tyrosine kinase inhibitors.
Lin L; Pan H; Li X; Zhao C; Sun J; Hu X; Zhang Y; Wang M; Ren X; Luo X; Shan G; Hui AM; Wu Z; Liu H; Tian L; Shi Y
Lung Cancer; 2022 Apr; 166():98-106. PubMed ID: 35248866
[TBL] [Abstract][Full Text] [Related]
15. Safety, efficacy, and pharmacokinetics of SH-1028 in EGFR T790M-positive advanced non-small cell lung cancer patients: A dose-escalation phase 1 study.
He J; Ma P; Zhao D; Shi X; Guo R; Gao W; Shu Y
Cancer; 2023 May; 129(10):1513-1522. PubMed ID: 36813747
[TBL] [Abstract][Full Text] [Related]
16. Aumolertinib-based comprehensive treatment for an uncommon site of EGFR exon 20 insertion mutations with multiple metastases non-small cell lung cancer: a case report.
Deng Y; Yang C; Liu W; Cai S; Guo X
Anticancer Drugs; 2022 Apr; 33(4):406-412. PubMed ID: 35266890
[TBL] [Abstract][Full Text] [Related]
17. Thoracic radiotherapy and concurrent almonertinib for unresectable stage III EGFR-mutated non-small-cell lung cancer: a phase 2 study.
Zhu L; Zou C; Zhang Z; Wang J; Yang L; Rao C; Yang Z; Liang J; Xia B; Shenglin MA
BMC Cancer; 2021 May; 21(1):511. PubMed ID: 33962566
[TBL] [Abstract][Full Text] [Related]
18. Aumolertinib Effectively Reduces Clinical Symptoms of an EGFR L858R-Mutant Non-Small Cell Lung Cancer Case Coupled With Osimertinib-Induced Cardiotoxicity: Case Report and Review.
Zhang Q; Liu H; Yang J
Front Endocrinol (Lausanne); 2022; 13():833929. PubMed ID: 35677717
[TBL] [Abstract][Full Text] [Related]
19. Sequence-dependent synergistic effect of aumolertinib-pemetrexed combined therapy on EGFR-mutant non-small-cell lung carcinoma with pre-clinical and clinical evidence.
Ao L; Fang S; Zhang K; Gao Y; Cui J; Jia W; Shan Y; Zhang J; Wang G; Liu J; Zhou F
J Exp Clin Cancer Res; 2022 May; 41(1):163. PubMed ID: 35501907
[TBL] [Abstract][Full Text] [Related]
20. Safety, Efficacy, and Pharmacokinetics of Rezivertinib (BPI-7711) in Patients With Advanced NSCLC With EGFR T790M Mutation: A Phase 1 Dose-Escalation and Dose-Expansion Study.
Shi Y; Zhao Y; Yang S; Zhou J; Zhang L; Chen G; Fang J; Zhu B; Li X; Shu Y; Shi J; Zheng R; Wang D; Yu H; Huang J; Zhuang Z; Wu G; Zhang L; Guo Z; Greco M; Li X; Zhang Y
J Thorac Oncol; 2022 May; 17(5):708-717. PubMed ID: 35181498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
